Related Experiment Video
Updated: Jan 15, 2026

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
Novel Pyrrolidine-Based Pyrazolines as α‑Glucosidase Inhibitors: Microwave-Assisted Synthesis, Antidiabetic Activity,
Bedriye Seda Kurşun Aktar1, Yusuf Sıcak2, Abdulkadir Bakırdöven1
1Department of Hair Care and Beauty Services, Yeşilyurt Vocational School, Malatya Turgut Özal University, Battalgazi, Malatya 44210, Türkiye.
Abstract:
Due to their unique properties, small multitargeted drugs containing a fluorinated aromatic moiety and nitrogenous heterocycles are widely available on the market. Considering the pharmacological significance of organofluorine and heterocyclic compounds, in this study, we synthesized a series of pyrazoline derivatives (14-27) containing a pyrrolidine moiety and substituted them with a fluorine atom or a fluorine-containing (-CF3 or -OCF3) group at different positions. Also, the antidiabetic activities of new pyrazolines were screened by in vitro α-glucosidase and α-amylase activity assays in order to investigate their potential use in the treatment of Diabetes Mellitus, one of the most common and rapidly spreading diseases of today. The findings of this research indicated that compound 21, having a trifluoromethoxy group at the ortho position of the pyrrolidine-based pyrazolines at the phenyl ring, was determined to be the most effective α-glucosidase inhibitor with IC50 values of 52.79 ± 6.00 μM, compared to acarbose (IC50: 121.65 ± 0.50 μM). Molecular modeling studies demonstrated the high specificity of the most active pyrazoline-pyrrolidine hybrid molecules to the active site of α-glucosidase and their potential to exert inhibitory effects through various interactions with basic residues. Furthermore, molecular dynamics simulations provided comprehensive information about the structural properties and binding mechanisms of the complexes.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Sulfonylureas
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

